Loading...
Please wait, while we are loading the content...
Similar Documents
Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial
| Content Provider | Scilit |
|---|---|
| Author | O'brien, Susan Brown, Jennifer R. Kingsley, C. Daniel Eradat, Herbert Pagel, John M. Lymp, James Hirata, Jamie Kipps, Thomas J. |
| Copyright Year | 2015 |
| Description | Key Points In this phase 1b study, obinutuzumab plus FC or B had acceptable safety, with infusion reactions the most common adverse event. Obinutuzumab plus FC or B showed promising clinical activity in the initial treatment of CLL, with no relapses to date. |
| Related Links | https://ashpublications.org/blood/article-pdf/125/18/2779/1384910/2779.pdf |
| Ending Page | 2785 |
| Page Count | 7 |
| Starting Page | 2779 |
| DOI | 10.1182/blood-2014-12-613570 |
| Journal | Blood |
| Issue Number | 18 |
| Volume Number | 125 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2015-04-30 |
| Access Restriction | Open |
| Subject Keyword | Hematology Research and Experimental Medicine Safety Antibody Efficacy Grade Cll Cri Orr Obinutuzumab Journal: Blood (Vol- 129, Issue- 18) |
| Content Type | Text |
| Resource Type | Article |